Ken Griffin Acumen Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.22 - $3.54 $37,740 - $60,180	17,000 Added 52.31%	49,500 $122,000
Q2 2024 Aug 14, 2024	BUY	$2.14 - $4.01 $49,006 - $91,829	22,900 Added 238.54%	32,500 $78,000
Q1 2024 May 15, 2024	SELL	$2.97 - $4.64 $9,504 - $14,847	-3,200 Reduced 25.0%	9,600 $38,000
Q4 2023 Feb 14, 2024	SELL	$1.86 - $4.48 $4,464 - $10,752	-2,400 Reduced 15.79%	12,800 $49,000
Q3 2023 Nov 14, 2023	SELL	$4.15 - $9.72 $15,355 - $35,964	-3,700 Reduced 19.58%	15,200 $63,000
Q2 2023 Aug 14, 2023	BUY	$3.59 - $6.59 $67,851 - $124,551	18,900 New	18,900 $90,000
Q4 2022 Feb 14, 2023	BUY	$4.81 - $10.17 $3,366 - $7,119	700 New	700 $3,000

41.8M

57.7K

749K

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $91.5M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.